Universal Influenza Vaccines 2018

16-18 April 2018, CHUV, University of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Join the conversation on Twitter – #UIV2017

Progress towards a Universal Influenza Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness.

UIV 2018 – this new forum will offer researchers an opportunity to discuss the characteristics of universal influenza vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such universal influenza virus vaccines.

The UIV 2018 Scientific Advisory Panel are calling for abstracts for both oral and poster presentation at the meeting.

Abstracts should be sent directly to the UIV 2018 Secretariat (John Herriot at Meetings Management) via the participation section.

Scientific Advisory Panel

Sarah Gilbert (Jenner Institute, University of Oxford, Oxford, UK)
Ted Ross (University of Georgia, Athens, Georgia, USA)
Sean Tucker (VAXART Inc., South San Francisco, California, USA)
John Oxford (Queen Mary University of London, London, UK)
Rob Lambkin-Williams (hVIVO Ltd, London, UK)
Justin Ortiz (World Health Organization, Geneva, Switzerland)
Erin Sparrow (World Health Organization, Geneva, Switzerland)
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)
Othmar Engelhardt (NIBSC, South Mimms, Potters Bar, UK)
Myra Widjojoatmodjo (Janssen Vaccines, Leiden, The Netherlands)
Tobias Kamphuis (Janssen Vaccines, Leiden, The Netherlands)
Anke Huckriede (University of Groningen, Groningen, The Netherlands)
Ron Babecoff (Biondvax Pharmaceuticals Ltd, Ness Ziona, Israel)
Tamar Ben-Yedidia (Biondvax Pharmaceuticals Ltd, Ness Ziona, Israel)
Harry Kleanthous (Sanofi US, Cambridge, Massachusetts, USA)

 

UIV 2018 Delegates

Login details will be supplied after you have registered for the event.


UIV 2018 Sponsors

  • hVIVO
  • Vismederi
  • FluConsult
  • ISIRV
  • BiondVax
  • VaxArt
  • APACI

UIV 2018 Downloads

UIV 2018 Leaflet

UIV 2018 Mailing List

Name
E-mail Address
What is 3+2-1?